<DOC>
	<DOCNO>NCT02308020</DOCNO>
	<brief_summary>The main purpose study evaluate safety effectiveness study drug know abemaciclib participant hormone receptor positive breast cancer , non-small cell lung cancer ( NSCLC ) , melanoma spread brain .</brief_summary>
	<brief_title>A Study Abemaciclib ( LY2835219 ) Participants With Breast Cancer , Non-small Cell Lung Cancer , Melanoma That Has Spread Brain</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>Have brain metastasis secondary hormone receptor positive breast cancer , NSCLC , melanoma . Have either human epidermal growth factor receptor 2 positive ( HER2+ ) ( Study Part A ) HER2 ( Study Part B ) breast cancer . Participants Study Part C must HR+ breast cancer , NSCLC , melanoma brain lesion clinically indicate surgical resection well consent provide tissue drug concentration determination 5 14 day study drug dose . Participants Part D must NSCLC subtype . Participants Part E must melanoma subtype . Participants Part F must HR+ breast cancer , NSCLC , melanoma leptomeningeal metastasis . For Parts A , B , D , E : Must least 1 measurable brain lesion ≥10 millimeter ( mm ) long diameter ( LD ) . For Part C ( surgical ) : Have metastatic brain lesion ( ) surgical resection clinically indicate . Have complete local therapy ( surgical resection , WBRT , SRS ) ≥14 day prior initiate abemaciclib recover acute effect . If receive concomitant corticosteroid , must stable decrease dose least 7 day prior baseline GdMRI . Have Karnofsky performance status ≥70 . Have life expectancy ≥12 week . For HR+ breast cancer participant part A , B , C , F : If currently receive endocrine therapy , participant may continue receive endocrine therapy provide extracranial disease stable least 3 month central nervous system ( CNS ) disease progression occur endocrine therapy . If condition meet , participant must discontinue endocrine therapy prior initiation abemaciclib . For HER2+ breast cancer participant part A , C , F : participant may receive concurrent treatment ( ongoing initiate simultaneously abemaciclib ) IV trastuzumab . For NSCLC participant part C , D , F : currently receive gemcitabine pemetrexed ( singleagent combination another therapy ) , participant may continue receive 1 2 therapy provide extracranial disease stable least 6 week CNS disease progression occur therapy . Have adequate organ function . Require immediate local therapy , include limited WBRT , SRS , surgical resection , treatment brain metastasis . Are take concurrent enzymeinducing antiepileptic drug ( EIAED ) . Have evidence significant ( ie , symptomatic ) intracranial hemorrhage . For Parts A , B , C , D , E : Have evidence leptomeningeal metastasis . Note : discrete dural metastasis permit . Have experience &gt; 2 seizure within 4 week prior study entry . For Parts A , B , D , E , F : Have previously receive treatment cyclin dependent kinase 6 ( CDK6 ) inhibitor . For Part C participant may receive prior palbociclib ribociclib , abemaciclib treatment . Have know contraindication GdMRI . Have preexist chronic condition result persistent diarrhea .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>